Targeting Myeloma Cells

Author: Dr. Ahmed Farhan     Published: 1 year ago 2 Replies

New drugs are being tested for the treatment of Multiple Myeloma to find the least toxic and most potent one.

Let's talk about how these drugs act.

Mezigdomide, a Cereblon E3 ubiquitin ligase modulator, targets  Ikaros and CK1α inhibiting tumor growth.

We need to know more about:

  • Ikaros
  • CK1α

to know about Mezigdomide.

Dr. Ahmed Farhan, 1 year ago

There is a recent study of mezigdomide plus dexamethasone in multiple myeloma patients.primary objectives were to evaluate the safety and efficacy of mezigdomide plus dexamethasone .

results were promising

ck1a

Regulates signaling pathways related to

membrane trafficking,

cell cycle progression,

chromosome segregation,

apoptosis,

autophagy,

cell metabolism, 

differentiation in development,

circadian rhythm(first kinase to have this activity),  immune response 

neurodegeneration

cancer

 

 

MUHAMMAD BILAL AMJAD, 1 year ago

Login to Reply